Ijin(14,900 +21.14%)Announced on the 11th that it has confirmed the neutralizing antibody titer similar to that of Modena’s vaccine in the nonclinical efficacy evaluation of the messenger ribonucleic acid (mRNA)-based COVID-19 vaccine (EG-COVID) under development. It is explained that it has proven its efficacy as a vaccine for the Corona 19 virus.
Neutralizing antibodies bind to the surface of virus particles and interfere with the binding of virus to cell receptors. This neutralizes the infectivity of the virus. It is used as the most important indicator when evaluating the defense against viruses in vaccine development, the company said.
In this neutralizing antibody efficacy evaluation test, the plaque inhibition test (PRNT) was used. This test method is a standard test method to evaluate the neutralizing antibody ability of antibodies produced in blood after vaccination. It was conducted by requesting an analysis agency under the Korea Centers for Disease Control and Prevention. As a result, the neutralizing antibody titer (IC50 titer), which inhibits the infection of the virus, was found to be at a level similar to the results of a nonclinical study of Moderna’s Corona 19 vaccine. Through this, it confirmed the possibility that EG-COVID will show comparable efficacy even compared to Modena’s vaccine, which is being vaccinated worldwide.
An official from I-Gene said, “It was confirmed that EG-COVID, a freeze-dried formulation, formed a neutralizing antibody equivalent to that of Modena’s COVID-19 prevention vaccine, which is a liquid formulation.” “It means that it is possible to develop a vaccine based on mRNA that can be stored in a refrigerator, overcoming the shortcomings of the company.”
“The main core technology of mRNA vaccines is the mRNA delivery system, but Modena and Pfizer use lipid nanoparticles (LNP) containing polyethylene glycol (PEG) as the delivery system.” “A situation that is presumed to be the cause of the systemic allergic reaction’anaphylaxis’ observed in some,” he said.
The carrier of EG-COVID does not contain PEG. Cationic liposomes are used as carriers. The safety of the shingles prevention vaccine’EG-HZ’ was confirmed in an Australian clinical trial. It is expected to have strengths in terms of safety compared to existing mRNA vaccines.
Ijin has completed a domestic patent application for the mRNA delivery system and EG-COVID composition. In the future, it plans to apply for patents in major countries and enter clinical trials by discussing with the Korea Food and Drug Administration.
Reporter Minsoo Han [email protected]
Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution